The 5-HT 7 receptor is a GPCR that is the target of a broad range of antidepressant and antipsychotic drugs. Various studies have demonstrated an ability of the 5-HT 7 receptor to modulate glutamatergic neurotransmission and cognitive processes although the potential impact upon AMPA receptors has not been investigated directly. The purposes of the present study were to investigate a direct modulation of the GluA1 AMPA receptor subunit and determine how this might influence AMPA receptor function.
Introduction
The 5-HT 7 receptor has been cloned from various species and is a member of the GPCR superfamily (Hoyer et al., 1994; Alexander et al., 2015a) . receptor signals via an increase in cAMP production as well as various other pathways (Shen et al., 1993; see Gellynck et al., 2013) and is the focus of various projects to identify novel therapeutics to treat conditions such as depression, sleep disorders and cognitive deficits (Mnie-Filali et al., 2007) . Further clinical interest in the 5-HT 7 receptor arises from a broad range of antidepressant and antipsychotic drugs displaying relatively high affinity for the receptor (Roth et al., 1994) . Further, two nonselective 5-HT 7 receptor antagonists have recently received marketing authorisation for the treatment of psychiatric conditions: lurasidone and vortioxetine (Fountoulakis et al., 2015; Sanchez et al., 2015) .
Expression of the 5-HT 7 receptor is apparent throughout the body with notable expression in the brain and spinal cord, vascular system and gastrointestinal tract (Waeber and Moskowitz, 1995; Gustafson et al., 1996; Stowe and Barnes, 1998; Neumaier et al., 2001) . Within the brain, there is prominent expression within the hippocampus (Waeber and Moskowitz, 1995; Gustafson et al., 1996; Neumaier et al., 2001; Mengod et al., 2010) , where homodimerization and heterodimerisation with the 5-HT 1A receptor may be relevant . At the cellular level within the hippocampus, expression in glutamatergic pyramidal neurones is evident (Neumaier et al., 2001) , which is consistent with a number of independent studies demonstrating that the 5-HT 7 receptor mediates excitation of glutamatergic pyramidal neurones and associated network activity (Bacon and Beck, 2000; Bickmeyer et al., 2002; Gill et al., 2002; Tokarski et al., 2003 Tokarski et al., , 2005 Costa et al., 2012) . Such neurophysiological actions may underlie the improvement in cognitive performance following 5-HT 7 receptor activation (Meneses, 2004; Perez-Garcia and Meneses, 2005; Eriksson et al., 2008; Freret et al., 2014) , which is consistent with the reduced cognitive performance following inhibition of 5-HT 7 receptor function by pharmacological antagonism or genetic manipulation (Meneses, 2004; Ballaz et al., 2007; Sarkisyan and Hedlund, 2009; Freret et al., 2014 ; but see Horisawa et al., 2011 and Waters et al., 2012) . However, some types of memory deficit are improved by 5-HT 7 receptor antagonists (McLean et al., 2009; Bonaventure et al., 2011; Nikiforuk et al., 2013) , which may be a consequence of different neurochemical mechanisms (Bonaventure et al., 2011) or biased signalling; this is consistent with the beneficial effects of some non-selective 5-HT 7 receptor antagonists used to treat psychiatric conditions (Horiguchi et al., 2011) .
In terms of a molecular mechanism by which the 5-HT 7 receptor might drive neuronal excitation in the hippocampus, recent evidence demonstrates that the 5-HT 7 receptor mediates phosphorylation of NMDA glutamate receptors with a consequential increase in NMDA receptor signalling (Vasefi et al., 2013) . Consistent with these findings, 5-HT 7 receptor knock-out mice display reduced LTP in the hippocampus (Roberts et al., 2004) . It should be noted, however, that 5-HT 7 receptor knock-out mice also display impaired contextual fear conditioning -a hippocampus-dependent phenomenon -but no deficit in spatial learning (Roberts et al., 2004) , which implicates 5-HT 7 receptor modulation of AMPA receptor neurotransmission (Zamanillo et al., 1999) . In support of this, 5-HT 7 receptors enhance AMPA receptor-mediated transmission in the hippocampus via an action on postsynaptic neurones (Costa et al., 2012) .
In the present study, we have investigated the ability of the 5-HT 7 receptor to alter glutamatergic neurotransmission in the hippocampus and have demonstrated that activation of the receptor promotes PKA-mediated phosphorylation of native GluA1 AMPA receptor subunits in rat hippocampus, which results in an increased insertion of the Ser 845 -phosphorylated GluA1 (pGluA1(Ser 845 ) subunit, into the neuronal membrane. This change is likely to contribute to the observed increase in AMPA receptormediated neurotransmission in the hippocampus both in vitro and in vivo. These Tables list key protein targets and ligands in this article which are hyperlinked to corresponding entries in http://www.guidetopharmacology. org, the common portal for data from the IUPHAR/BPS Guide to PHARMACOLOGY (Pawson et al., 2014) and are permanently archived in the Concise Guide to PHARMACOLOGY 2015/16 ( a,b,c Alexander et al., 2015a,b,c) .
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Methods
Animals
All animal care and experimental protocols were in accordance with the European Communities Council Directive 2010/63/ EU and Italian or UK legislation acts concerning animal experimentation and were approved by the Local Ethics Committees. Efforts were made to minimize animal suffering and to reduce the number of animals used. All in vivo experiments were performed and are reported in accordance with the ARRIVE guidelines (Kilkenny et al., 2010; McGrath and Lilley, 2015) . ) and streptomycin (100 μg•mL
Preparation of rat neurone or astrocyte cultures
À1
). Cells were grown at 37°C, 5% CO 2 , and half the volume of the medium was replaced after 4 days with complete medium minus glutamate. For all assays, primary cells were used between 8 and 10 days in culture.
Phenotype and purity of cell cultures
Purity of cultured cells was assessed by phenotyping with primary antibodies {rabbit anti-glial fibrillary acidic protein (GFAP); 1:1000 (Sigma-Aldrich) or anti-NeuN [mouse 1:200 (Chemicon; Merck Millipore (Darmstadt, Germany))]}, with five fields per coverslip acquired using a Leica (Wetzlar, Germany) microscope (IM 50 programme; 20× objective) with positive cells counted manually.
RNA extraction and quantification
Total RNA from cultured cells was extracted using RNeasy mini kit from Qiagen (Qiagen Inc, Valencia, CA, USA) following the manufacturer's instructions. Genomic DNA was removed using RNAse-free DNase I (Applied Biosystems, Life Technologies). Purified RNA was quantified using an Agilent 2100 Bioanalyzer following the Agilent RNA 6000 Nano kit protocol (Agilent Technologies Inc).
Reverse transcribed PCR
cDNA was generated by reverse transcription of total RNA (100 ng) using TaqMan Reverse Transcription Reagents (Applied Biosystems, Life Technologies): 1× reverse transcription buffer, MgCl 2 (2.5 mM), deoxynucleotides (1 mM), random hexamers (2.5 μM), RNase inhibitor (0. 
Assessment of cAMP concentration
cAMP was quantified using the cAMP Hi Range kit (Cisbio, Bagnois-sur-Ceze, France) according to the manufacturer's instructions.
Sample preparation and measurement of total CREB, pCREB, and phospho-p38 MAPK Cells were removed by scraping in lysis buffer [Tris (10 mM; pH 7.4), NaCl (100 mM), EDTA (1 mM), EGTA (1 mM), NaF (1 mM), Na 4 P 2 O 7 (20 mM), Na 3 VO 4 (2 mM), 1% Triton X-100, 10% glycerol, 0.1% sodium dodecyl sulfate, 0.5% deoxycholate, PMSF (2 mM), protease inhibitors (Complete Mini, Roche Life Science, Sigma-Aldrich) and 1% phosphatase inhibitors I and II (Sigma-Aldrich)]. Cells lysates were incubated at 4°C for 30 min before centrifugation (10 min at 13 000 × g) and the supernatants quantified for total cAMP response element-binding protein (CREB) 
Isolation of cell surface proteins
Cell surface proteins were isolated using EZ-link sulfo-NHS-SS-Biotin (Pierce) at 4°C. Cells were incubated with biotin (1 mg•mL À1 ; 20 min) and dissolved in PBS. After three rinses in ice-cold glycine (50 mM) in PBS, cells were scraped into homogenization buffer (0.1% sodium dodecyl sulfate, 0.5% NP40, 0.5% sodium deoxycholate, 150 mM NaCl, complete mini protease inhibitors, phosphatase inhibitors cocktail I and II in PBS; pH 7.4) and centrifuged (10 000 × g; 20 min), and the supernatant represented the total protein extract.
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For purification of the biotinylated surface protein fraction, 50 μg of total proteins was incubated with 80 μL of 50% slurry Neutravidin resin (Pierce) for 2 h at 4°C. After washing, biotinylated proteins were eluted [100 μL of elution buffer; Invitrogen NuPage LDS sample buffer with ditiothreitol (50 mM)], heated at 95°C for 5 min before centrifugation (1000 × g for 2 min). Protein concentration was determined using Bio-Rad reagents (Bio-Rad Laboratories Inc., Hercules, CA, USA) based on the Bradford assay. When protein concentration was expected to be low, the micro BCA kit was used (Pierce).
SDS-PAGE Western blotting
Proteins were separated using SDS-PAGE in an XCell SureLock ™ Mini-Cell (Invitrogen, Life Technologies). Equal amounts of cell lysates (~6-10 μg protein) in 4× NuPAGE® LDS Sample Buffer and 10× NuPAGE Sample Reducing Agent were boiled for 5 min, centrifuged briefly and loaded in precast gels (1.5 mm 4-12% Novex Bis-Tris Pre-cast Mini Gels; Invitrogen, Life Technologies). Prestained protein MW markers (Novex® Sharp Pre-stained Protein Standard) were loaded in parallel. Electrophoresis was performed (50 V for 1 h), and proteins were transferred to PVDF membranes (Amersham plc, Little Chalfont, Bucks, UK) using a Mini Trans-Blot module (Bio-Rad) in transfer buffer (25 mM Tris, 192 mM Glycine, 20% methanol; pH 8.3) at 40-50 V for 2 h. PVDF membranes were blocked (5% skimmed dried milk in Tris-buffered saline (50 mM Tris HCl, 280 mM NaCl, 2.7 mM KCl, pH 7.6; 1 h) containing 0.1% and then incubated with the relevant primary antibodies; either rabbit anti-pGluA1(Ser 845 ) (Sigma-Aldrich; 1:1000), rabbit anti-GluA1 (Millipore; 1:1000), rabbit anti-pan cadherin (Abcam plc, Cambridge, UK; 1:1000) or mouse anti-GAPDH (Santa Cruz Biotechnology, Santa Cruz, CA, USA; 1:10 000). Membranes were washed (3 × 10 min) with 0.1% Tween-20 in Tris-buffered saline before incubation (1 h at room temperature) with peroxidase-conjugated secondary antibodies (goat antirabbit IgG-HRP or goat anti-mouse IgG-HRP, Santa Cruz; 1:5000). The chemiluminescence reaction was developed with ECL Plus (Amersham plc, Little Chalfont, Bucks, UK) and detected with Luminescent Image Analyzer LAS-4000 mini (Fujifilm, Tokyo, Japan). ODs were determined by densitometric analysis with Quantity One software (Bio-Rad).
Electrophysiological recording in the hippocampus in vivo
Adult male Sprague-Dawley rats (250-350 g, n = 12) (Charles River, Margate, UK) were initially anaesthetized with isoflurane and subsequently with chloral hydrate (400 mg•kg À1 i.p.) with anaesthetic depth maintained by constant i.v. infusion (80-120 mg•kg
À1
•h
) with adjustments, depending on corneal reflex, withdrawal response to paw pinch and the stability of monitored cardiovascular variables. Core body temperature was maintained at 37 ± 1°C. The right femoral vein, the artery and the trachea were cannulated to permit respectively the Figure 1 Expression of the 5-HT 7 receptor by hippocampal primary cells in culture, compared with the expression by primary cerebral cortex cells and adult rat hippocampal tissue. Representative RT-PCR of cDNA products of around 850 bp from adult rat hippocampi (Adult: lanes 5 and 6) and primary cells cultured from the hippocampi (Hipp: lanes 3 and 4) and cerebral cortices (Cx: lanes 1 and 2) of E18/19 rat embryos. Lanes 2, 4 and 6 show lack of product when the enzyme was omitted from the reverse transcription step. Each line of the ladder (M) represents a band size increase of 100 bp. Similar results were obtained from three independent experiments.
Figure 2
Ability of the 5-HT 7 receptor to increase cAMP levels in hippocampal neurones. (A) Concentration-dependent ability of 5-HT to increase intracellular cAMP levels. (B) Concentration-dependent ability of the selective 5-HT 7 receptor antagonist, SB258719, to inhibit the 5-HT (100 nM)-induced increase in cAMP levels and lack of inhibition by the selective 5-HT 4 and 5-HT 6 receptor antagonists (GR113808 and SB399885 respectively). Data represent the percentage of cAMP increase after 5-HT addition versus basal levels (mean ± SEM, n = 3). (C) Concentration-dependent ability of 5-HT to increase intracellular cAMP levels in the absence and presence of the selective 5-HT 7 receptor antagonist, SB258719 (100 nM); the rightward shift in the 5-HT concentration-response curve is indicative of competitive antagonism by SB258719. Data represent mean ± SEM, n = 3.
administration of supplemental anaesthetic, the recording of arterial BP via a pressure transducer and amplifier (Neurolog module NL108; Digitimer, Welwyn Garden City, UK) and the maintenance of a clear airway. Animals were placed in a stereotaxic frame (Narishige ST-7) and the dorsal brain surface overlying the hippocampus exposed by craniotomy. A small incision was made in the dura, and a multibarrel recording electrode (Kation Scientific, Minneapolis, MN, USA) was lowered vertically through the cortex to the CA3 pyramidal layer of the hippocampus according to the following stereotaxic boundaries (Paxinos and Watson, 1998) : Bregma À3.9 to 4.4 mm, lateral 3.7-4.2 mm and depth 3.6-4.2 mm below pial surface. Unitary activity was recorded through an extracellular carbon fibre microelectrode, and using the Neurolog system, the signal was amplified (×10 k, module NL104) and filtered (bandwidth 1-30 kHz, module NL125), with the conditioned output being captured on a PC using a micro1401 interface with Spike 2 software (CED). Multibarrel electrodes were filled with 5-carboxamidotryptamine (5-CT) (DP-5-CT, 1-10 mM), WAY-100,635 (1-10 mM), AMPA (5 mM in 195 mM NaCl; pH 8) and 2,3-dihydroxy-6-nitro-7-sulfamoylbenzo[f]quinoxaline-2,3-dione (NBQX) (disodium salt, 1 mM in double distilled H 2 O; pH 8) and for current balancing and recording site marking, Chicago Sky Blue. Initially, baseline CA3 pyramidal neurone activity was examined during iontophoretic administration of 5-CT alone and in the presence of the 5-HT 1A receptor antagonist WAY-100,635. Subsequent experiments examined the response to 5-CT, with and without concomitant application of WAY-100,635, on neuronal bursts of firing induced by cyclical (5/30 s) iontophoretic administration of AMPA. NBQX was iontophoretically administered at the end of experiments to confirm that AMPA-induced excitations were selective. Stable baseline or AMPA-evoked neuronal activity was recorded for a minimum of 5 min before test substance examination. Neurones with unstable activity or whose recording location lay outside the pyramidal layer were excluded from analyses. Neuronal activity was measured in spikes per second (Hz) for a minimum period of 60 s before and during test compound treatment.
Subsequent to electrophysiological recordings in vivo, rats were killed without recovery of consciousness by an overdose of sodium pentobarbitone (200 mg•kg À1 ), followed by cervical dislocation.
Electrophysiological recording in the hippocampus in vitro
Male Sprague-Dawley rats (6-8 weeks old) were killed by anaesthetic overdose using isoflurane inhalation. Transverse hippocampal slices (400 μm thickness) were cut using a vibratome (Leica VTS1000) in chilled (<4°C) carbogenated (95% O 2 /5% CO 2 ) artificial CSF (NaCl, 127 mM; KCl, 1.9 mM; KH 2 PO 4 , 1.2 mM; CaCl 2 , 2.4 mM; MgCl 2 , 1.3 mM; NaHCO 3 , 26 mM; D-glucose, 10 mM). Slices were maintained in artificial CSF at room temperature for a minimum of 1 h before transferring to a custom-built recording chamber to commence wholecell recordings from hippocampal CA3 pyramidal neurones with an Axopatch 1D amplifier (Molecular Devices LLC, Sunnyvale, CA, USA), using the blind version of the patch clamp technique (Pickering et al., 1991) . Patch pipettes were pulled from thin-walled borosilicate glass (GC150-TF10, Harvard Apparatus) with resistances between 3 and 8 MΩ when filled with intracellular solution of the following composition: Kgluconate, 130 mM; KCl, 10 mM; EGTA-Na, 1 mM; HEPES, 10 mM; Na 2 ATP, 4 mM; Na 2 GTP, 0.3 mM; Lucifer yellow, 2 mM; pH adjusted to 7.4 with KOH and osmolarity adjusted to 310 mOsm with sucrose. Data were filtered at 2-5 kHz (current clamp) or 1 kHz (voltage clamp), digitized at 10 kHz (Digidata 1322; Molecular Devices LLC) and recorded on a PC running Clampex 9.1 software (Molecular Devices LLC). After achieving whole-cell access, current/voltage relations were generated to identify intrinsic membrane conductances consistent with CA3 pyramidal neurones. In voltage clamp experiments, mossy fibre pathway synaptic inputs were stimulated using a concentric bipolar stainless steel electrode and AMPA receptormediated EPSCs pharmacologically isolated using D-AP5 (25 μM), bicuculline (10 μM) and CGP-55845 (200 nM) to block NMDA, GABA A and GABA B receptor-mediated synaptic inputs respectively. Where relevant, 5-HT 1A receptors were also blocked with WAY-100,635 (1 μM) prior to obtaining a stable baseline of at least 5 min and then examining the effect of 5-CT (10 μM) application, before a final period of wash and confirmation of AMPA-mediated responses with NBQX (10 μM). In current clamp experiments, a minimum of two stable responses were obtained to AMPA application (10-20 μM, 2-6 s) in the presence of WAY-100,635 (1 μM) and tetrodotoxin (1 μM), before repeating in the presence of 5-CT (10 μM), a period of wash and, where possible, perfusion of SB258719 (20 μM) and a further 5-CT response examination. After completion of experiments, slices were fixed in 4% paraformaldehyde for a minimum of 48 h, before clearing with DMSO (>4 h), and visualisation of recorded cells using fluorescence microscopy to confirm their location within the CA3 pyramidal layer and characteristic morphology.
Data and statistical analysis
The data and statistical analysis in this study comply with the recommendations on experimental design and analysis in pharmacology (Curtis et al., 2015) . Where variance is indicated, data shown are means ± SEM. Drug concentration-response curves were fitted to a four parameter logistic equation using GraphPad Prism 5 (GraphPad Software Inc., San Diego, CA, USA). Agonist potency was expressed as pEC 50 (Àlog EC 50 ). The inhibition of antagonists was expressed as the pIC 50 (ÀlogIC 50 ), where IC 50 represents the concentration of drug inhibiting 50% of agonist maximal response. pK B values for antagonists were determined using the equation pK B = (Àlog([antagonist]/(concentration ratio À 1)) where concentration ratio = ratio of the agonist EC 50 in the presence and absence of the antagonist.
For biochemical assays, where required, normalisation was a % change from the control group's individual value for a given experiment with individual values and then used to generate means ± SEM. Statistical analysis was only performed if the n-value was 5 or greater. Where more than two groups were compared, a Kruskal-Wallis ANOVA was performed. If P < 0.05 from the Kruskal-Wallis ANOVA or where just two groups were to be compared, a Mann-Whitney U-test was performed with P < 0.05 considered a statistically significant difference between groups.
Analysis of electrophysiological data was carried out using Clampfit 9.1 software (Molecular Devices LLC). For voltage clamp data, the mean maximum electrically-evoked EPSC amplitude measured from a minimum of five consecutive sweeps (60 s) was compared with a temporally matched period during the peak response to 5-CT. For current clamp data, the AUC (in V·ms À1 ) of AMPA-evoked responses was the primary measurement; the baseline was taken as the response immediately preceding 5-CT perfusion. All data are represented as mean ± SEM. Comparisons between treatment periods were made using the paired Student's t-test. Probability (P) values <0.05 were considered significant. Hippocampal 5-HT 7 receptors signal phosphorylation BJP SB258719, SB399885 and WAY-100,635 were from Tocris Bioscience, Ellisville, MO, USA. Laboratory reagents were from Sigma-Aldrich unless otherwise specified. Cell culture reagents were purchased from Gibco/Invitrogen (Life Technologies, Paisley, UK), except where otherwise indicated.
Results
5-HT 7 receptor mRNA expression in primary culture of hippocampal cells The purity of primary cell cultures after 8-10 days in vitro was evaluated by immunocytochemistry for the neuronal marker NeuN and the astrocyte marker GFAP; the percentage of hippocampal NeuN-and GFAP-positive cells vs. DAPI-stained cells was around 80% and 10%, respectively (Supporting Information Figure S1 ). At the same end-point of 8-10 days in vitro, expression of 5-HT 7 receptor mRNA was evident by RT-PCR with appropriate sized product detected from cultured hippocampal cells (and also cultured cerebral cortex cells and adult hippocampus; Figure 1 ). Hereafter the hippocampal primary cells enriched considerably for neurones using appropriate culture conditions will be termed hippocampal neurones.
Ability of 5-HT to increase intracellular cAMP levels in hippocampal neurones and pharmacological definition of the receptor 5-HT displayed a concentration-dependent ability to increase cAMP levels in hippocampal neurones (pEC 50 of 7.2 ± 0.2; Hill slope of 1.2 ± 0.2; Figure 2A ). Neither the selective 5-HT 4 receptor antagonist, GR113808, nor the selective 5-HT 6 receptor antagonist, SB399885 (either at concentrations up to 1.0 μM), prevented the ability of a sub-maximal concentration of 5-HT (100 nM) to increase cAMP levels (the increase in cAMP levels evident at the relatively high micromolar concentrations of SB399885 may be a consequence of engagement with additional receptors; Hirst et al., 2006) . In contrast, the selective 5-HT 7 receptor antagonist, SB258719, prevented the ability of 5-HT (100 nM) to increase cAMP levels in a concentration-dependent manner (pIC 50 of 7.95 ± 0.09, n = 3; Figure 2B ). Furthermore, SB258719 displayed competitive antagonism of the 5-HT-evoked response (pK b of 8.23 ± 0.1; Figure 2C ). Amount of proteins was normalized using GAPDH and pan cadherin in the total cell extract and in the cell surface fraction respectively. Values are expressed as fold increase ±SEM with respect to basal levels from seven [5-HT (5 min)] or four independent experiments *P < 0.01, 5-HT (5 min) versus basal; Mann-Whitney U-test.
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Influence of 5-HT 7 receptors upon pCREB levels in hippocampal neurones
5-HT (1 μM) increased the relative pCREB levels (pCREB :-CREB ratio) above basal levels although the signal was transient (evident at 5 min of incubation with 5-HT but not at 10 min and longer; Figure 3A ). Prior incubation with SB258719 (100 nM to 10 μM) inhibited the ability of 5-HT (5 min) to increase relative pCREB levels in a concentrationdependent manner ( Figure 3B ). 5-HT (1 μM) failed to modify phosphorylated p38 MAPK levels in the hippocampal neurones (Supporting Information Figure S2 ). This contrasted the ability of 5-HT (1 μM) to increase phosphorylated p38 MAPK levels in rat primary astrocytes (Supporting Information Figure S2 ), the latter being consistent with previous studies (e.g. Lieb et al., 2005) .
Influence of 5-HT 7 receptors upon GluA1 expression and post-translational modification in hippocampal neurones
In hippocampal neurones, either 5-HT (1 μM; 5 min) or forskolin (10 μM; 5 min) increased the relative total GluA1 protein level and to a greater extent the relative protein level of pGluA1(Ser 845 ) (Supporting Information Figures S3 and 4) .
The prior application of either GR113808 (up to10 μM) or SB399885 (up to 10 μM) failed to block the effects of 5-HT on the relative total GluA1 or pGluA1(Ser 845 ) protein levels, whereas SB258719 (10 μM) reduced the ability of 5-HT to increase relative pGluA1(Ser 845 ) protein levels ( Figure 4) although not total GluA1 protein levels ( Figure 4B ). Similar to 5-HT, the selective 5-HT 7 receptor agonist AS-19 (1 μM) increased relative levels of pGluA1 (Ser 845 ) and the action of AS-19 was prevented completely by prior application of SB258719 (10 μM; Figure 4 ). However, AS-19 (1 μM) did not increase total GluA1 protein levels ( Figure 4C ). This lack of activity associated with AS-19 and the failure of SB258719 (10 μM) to prevent the 5-HT-induced increase in total GluA1 protein levels suggest that the latter effect was not mediated via the 5-HT 7 receptor.
Influence of 5-HT 7 receptors upon cell surface GluA1 AMPA receptor expression in hippocampal neurones
Treatment of hippocampal neurones with 5-HT (1 μM) increased cell surface membrane expression of pGluA1 (Ser 845 ) for the three time points investigated (5, 10 and 30 min; Figure 5 ). In contrast, no difference in the cell surface levels of GluA1 was detected ( Figure 5 ).
The ability of 5-HT (1 μM) to increase cell surface membrane expression of pGluA1 (Ser 845 ) was prevented by prior application of either SB258719 (10 μM; Figure 6 ) or the PKA inhibitor, H89 (10 μM; Figure 6 ). As demonstrated in other experiments, SB258719 (10 μM) also inhibited the 5-HT-induced increase in pGluA1 (Ser 845 ) in the total cell extracts, as did H89 (10 μM; Figure 6 ).
Ability of PDE 4 and PDE 10 to regulate 5-HT-induced pGluA1(Ser 845 ) in hippocampal neurones
In hippocampal neurones, either the PDE4 inhibitor, rolipram (10 μM), or the PDE10 inhibitor, papaverine (10 μM), increased levels of pGluA1 (Ser 845 ) (Supporting Information Figure S4 ), which were further increased by combination with 5-HT (1.0 μM) to levels above those detected with 5-HT (1 μM) alone (Supporting Information Figure S4 ). In contrast, neither rolipram nor papaverine altered levels of total GluA1 when applied alone or in combination with 5-HT (Supporting Information Figure S4 ).
Ability of the 5-HT 1A/7 receptor agonist 5-CT to alter the firing pattern of hippocampal CA3 neurones in vivo Extracellular recordings were performed in anaesthetized rats (n = 12) examining the effects of iontophoretic administration of the 5-HT 1A/7 receptor agonist, 5-CT (for electrode placement see Supporting Information Figure S5 ). In all, recordings were made from 16 hippocampal CA3 pyramidal neurones, of which 50% (8/16) were active (firing rate of 7.9 ± 3.0 Hz), whilst the remaining were quiescent. In seven of these active neurones, 5-CT administration was tested on baseline activity, with neuronal activity significantly reduced from 15.1 ± 2.8 to 9.7 ± 3.7 Hz in four of these seven neurones and activity increasing from 0.8 ± 0.4 to 4.9 ± 1.7 Hz in the remaining three neurones ( Figure 7A and C) . To remove the potentially confounding effect of 5-HT 1A receptor activation by 5-CT, the selective 5-HT 1A receptor antagonist, WAY- (Ser 845 ) levels in the total cell extracts and in the cell surface fractions. Amount of proteins was normalized using GAPDH and pan cadherin in the total extract and in the cell surface fraction respectively. Values are expressed as fold increase ±SEM with respect to basal levels from seven (5-HT) or three independent experiments. *P < 0.01, 5-HT versus basal; Mann-Whitney U-test. 100,635, was applied to seven neurones, which revealed an almost exclusively excitatory response to 5-CT; the firing rate of six of these seven neurones was increasing significantly from a mean of 6.2 ± 2.2 to 11.5 ± 2.5 Hz (P < 0.05, n = 6; Figure 7A and D). Only a single neurone (1/7) was activity reduced (from 12.7 to 6.2 Hz; Figure 7A ).
The effects of 5-CT were also examined on bursts of action potential firing of hippocampal CA3 pyramidal neurones induced by cyclical administration of AMPA. When tested with 5-CT alone, AMPA-evoked firing was significantly reduced in the majority (6/7) of neurones (from 29.0 ± 12.0 to 13.6 ± 6.2 Hz; Figure 7B ) and in the remaining neurone firing increased from 6.3 to 7.9 Hz ( Figure 7B ). However, in the presence of the selective 5-HT 1A receptor antagonist WAY-100,635, a predominant excitatory action of 5-CT was revealed, with AMPA-induced neuronal firing increased significantly in five of these seven neurones (from 28.6 ± 8.7 to 50.1 ± 13.8 Hz; Figure 7B and E) with the activity of the remaining two neurones being reduced from 13.2 to 3.9 Hz ( Figure 7B ).
Ability of the 5-HT 7 receptor to modify synaptic input into hippocampal CA3 pyramidal neurones in vitro
To determine whether 5-HT 7 receptor activation could modify the magnitude of AMPA receptor-mediated synaptic input to CA3 pyramidal neurones, whole-cell patch clamp recordings were performed from rat hippocampal slices, electrically stimulating mossy fibre inputs to evoke EPSCs (for electrode placement, see Supporting Information Figure S5 ). In the presence of the 5-HT 1A receptor antagonist, WAY-100,635 (1.0 μM), the 5-HT 1A/7 receptor agonist, 5-CT (10 μM), revealed a mixed response with EPSC amplitude reduced to 62.4 ± 1.6% of control levels in three of the nine neurones (from 77.2 ± 23.0 to 48.8 ± 15.6 pA; Figure 8A , C top and D) and enhanced to 150.8 ± 14.5% of control levels in six of the nine neurones (from 69.6 ± 15.2 to 101.9 ± 20.5 pA; P < 0.05, n = 6; Figure 8B , C bottom and D). Both these responses partially recovered to pre-5-CT application levels upon washout of 5-CT (to 72.4 ± 24.3 and 86.2 ± 17.5 pA respectively). EPSCs were confirmed as AMPA receptor mediated via administration of the selective AMPA receptor antagonist, NBQX (10 μM), which abolished EPSC amplitude ( Figure 8A-D) .
Further patch clamp experiments were performed to determine the effects of 5-HT 7 receptor activation upon isolated postsynaptic AMPA receptor-mediated activity by examining the effects of 5-CT (10 μM) administration, in the presence of tetrodotoxin (1 μM) and WAY-100,635 (1 μM), upon short periods of depolarisation induced by brief perfusion with AMPA (20 μM). These current clamp experiments revealed an almost exclusive augmentation of AMPA-induced depolarisation by 5-CT (10 μM), with the AUC of eight neurones enhanced significantly from 1169 ± 167 to 1827 ±-284 V·ms À1 (156.8 ± 10.4% of control; P < 0.01, n = 8; Figure- 9A, B and D), with recovery following washout of 5-CT (to 1262 ± 236 V·ms À1 , 104.7 ± 10.0% of pre-5-CT application;
Figure 7
Iontophoretic administration of the 5-HT 1A/7 receptor agonist 5-CT induced a predominant excitation in the baseline and AMPA-induced firing of hippocampal CA3 pyramidal neurones in the presence of the 5-HT 1A receptor antagonist WAY-100,635, in vivo. (A) Group data revealed a mixed excitatory/inhibitory response to 5-CT administration on baseline neurone firing in the absence of WAY-100,635, which was modified to an almost exclusively excitatory response during 5-HT 1A receptor blockade; neurone numbers are overlaid histograms of change in firing rate (in Hz). (B) Similarly, in the absence of WAY-100,635, 5-CT application depressed AMPA-evoked firing, whereas in the presence of WAY-100,635, 5-CT predominantly enhanced AMPA-evoked bursts of activity; neurone numbers are overlaid histograms of change in firing rate (in Hz). (C,E) Typical examples of 5-CT inducing an increase in baseline neuronal activity in the absence of WAY-100,635 (C), an increase in neuronal activity in the presence of WAY-100,635 (D) and an enhancement of AMPA-evoked firing in the presence of WAY-100,635, with demonstration of AMPA receptor mediation using NBQX also shown (E). *P < 0.05 versus basal levels; paired Student's t-test.
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F Andreetta et al. Figure 9D ). In three neurones, AUC analysis revealed a similar mean control 5-CT increase to 157.2 ± 4.7% of AMPA responses (n = 3), which was reduced to 111.0 ± 14.7%, when repeated in the added presence of the 5-HT 7 receptor antagonist SB258719 (1 μM; Figure 9C and D).
Discussion
The present studies originated to better understand the mechanisms that might underlie the ability of the 5-HT 7 receptor to modulate glutamate-mediated neurotransmission (Bacon and Beck, 2000; Bickmeyer et al., 2002; Gill et al., 2002; Tokarski et al., 2003 Tokarski et al., , 2005 Costa et al., 2012) , which may have relevance to the ability of the 5-HT 7 receptor to modulate memory and learning (Meneses, 2004; Perez-Garcia and Meneses, 2005; Ballaz et al., 2007; Eriksson et al., 2008; Sarkisyan and Hedlund, 2009; Horisawa et al., 2011; Waters et al., 2012; Freret et al., 2014) and relevant physiological phenomena such as long-term potentiation. Initially, our investigations used primary cultures of rat hippocampus under suitable conditions to favour the culture of neurones. The cultured hippocampal neurones expressed 5-HT 7 receptor transcripts, and pharmacological studies demonstrated that activation of the 5-HT 7 receptor increased cAMP levels as well as the phosphorylation of the downstream signalling transcription factor, CREB. A key finding in the present study was that 5-HT 7 receptor activation signalled via the cAMP-dependent kinase, PKA, by phosphorylation of Ser 845 within the C-terminal tail of the GluA1 AMPA receptor subunit. This post-transcriptional modification promoted expression of the pGluA1(Ser 845 ) subunit in the neuronal surface membrane. Glutamate AMPA receptors are the primary means of relaying excitatory synaptic neurotransmission, and regulation of their function alters synaptic plasticity and associated memory function. It is well established that phosphorylation of AMPA receptor subunits modifies their activity (Song and Huganir, 2002) . The GluA1 subunit forms homomeric receptors and also contributes a major component of the predominant heteromeric AMPA receptor (GluA1/2) in the hippocampus (Lu et al., 2009) . The GluA1 AMPA receptor subunit contains two phosphorylation sites, Ser 831 and Ser
845
. The Ser 831 is a substrate for calcium/calmodulin-dependent protein kinase and PKC (Roche et al., 1996; Barria et al., 1997; Mammen et al., 1997) , whereas Ser 845 is a substrate for PKA (Roche et al., 1996) .
Relevant to the present study, phosphorylation of Ser 845 within
Figure 8 GluA1 subunits by directly enhancing cAMP levels (via either direct stimulation of adenylate cyclase by forskolin or inhibition of PDE by rolipram) promotes cell surface expression of the pGluA1(Ser 845 ) subunit (Esteban et al., 2003; Oh et al., 2006) and promotes AMPA receptor function (Roche et al., 1996; Lee et al., 2000; Oh et al., 2006; He et al., 2009; Makino and Malinow, 2009) . In the present studies, activation of the 5-HT 7 receptor increased cell surface expression of pGluA1 (Ser 845 ) via a PKAdependent mechanism, consistent with the 5-HT 7 receptor elevating cAMP levels. The involvement of the 5-HT 7 receptor was indicated by a number of lines of evidence. Thus, 5-HT 7 receptor transcripts were expressed by the primary neurones in culture, and their functional involvement was verified pharmacologically by the action of the selective 5-HT 7 receptor agonist AS-19 at a just-maximal concentration to activate the 5-HT 7 receptor (1 μM; Brenchat et al., 2009) , action comparable to that of 5-HT (pEC 50 = 7.2). The apparent lower efficacy of AS-19 compared with 5-HT may reflect the partial agonist action of AS-19 demonstrated in other assays in vitro (Brenchat et al., 2009) . Furthermore, the relatively selective 5-HT 7 receptor antagonist, SB258719 (Thomas et al., 1998 (Thomas et al., , 1999 , antagonized the 5-HTevoked responses. SB258719 also displayed competitive receptor antagonism of the 5-HT-induced increase in cAMP levels within the primary hippocampal cultures generating a pK b of 8.23, consistent with the affinity of SB258719 for the 5-HT 7 receptor (Thomas et al., 1998 (Thomas et al., , 1999 . Furthermore, two additional 5-HT receptor subtypes known to increase cAMP production, the 5-HT 4 and 5-HT 6 receptors, did not appear relevant to the responses detected in the present studies because the selective 5-HT 4 and 5-HT 6 receptor antagonists, GR113808 (Gale et al., 1994) and SB399885 (Hirst et al., 2006) , failed to inhibit 5-HTinduced elevated cAMP levels in the hippocampal primary cell cultures at pharmacologically relevant concentrations (up to 1 μM). Involvement of cAMP was also indicated by the effect of PDE inhibition; thus, 5-HT 7 receptor-mediated phosphorylation of GluA1 was increased by the non-selective PDE4 and PDE10 inhibitors, rolipram and papaverine, respectively, with both PDE4 and PDE10 known to be expressed in hippocampus (Menniti et al., 2006) . Consistent with the biochemical studies demonstrating that the 5-HT 7 receptor promoted expression of the pGluA1(Ser 845 ) subunit in the neuronal membrane of cells derived from all fields of the hippocampus, electrophysiological recordings in the CA3 field of the hippocampus in vivo revealed that 5-HT 7 receptor activation increased spontaneous activity and enhanced AMPA-induced increases in action potential firing. Furthermore, electrophysiological recordings in vitro demonstrated that whilst selective AMPA receptor- mediated synaptic transmission via mossy fibre inputs to CA3 pyramidal neurones could be enhanced or depressed in the presence of 5-CT, AMPA-induced whole-cell postsynaptic currents were consistently increased by 5-HT 7 receptor activation. The present studies confirmed the role of 5-HT 7 receptors in the regulation of CREB phosphorylation in hippocampal neurones (Mahgoub et al., 2006) . In contrast,5-HT had no effect on p38 MAPK in the same preparation, despite studies run in parallel that demonstrated that 5-HT did increase p38 MAPK phosphorylation in rat cortical astrocytes in culture, which also expressed 5-HT 7 receptor mRNA (data not shown). The latter is consistent with previous studies (Lieb et al., 2005; Mahe et al., 2005) , and hence, our data suggest differential cell signalling for the 5-HT 7 receptor in neurones compared with astrocytes.
As well as the relatively short-term actions of 5-HT 7 receptors investigated in the present studies, relevant longer-term actions mediated via the 5-HT 7 receptor are also evident including elevation in glutamate levels in vivo, indicating enhanced excitatory synaptic tone (Canese et al., 2015) and plastic neuronal remodelling (Kvachnina et al., 2005; Kobe et al., 2012; Speranza et al., 2013; Canese et al., 2015) , which may underlie structural changes associated with memory formation.
Interestingly, a previous report suggests activation of the 5-HT 1B receptor evokes calcium/calmodulin-dependent protein kinase-mediated phosphorylation of the GluA1 subunit at a further phosphorylation site in the C-terminus, Ser 831 , which also contributes to 5-HT-induced potentiation of neurotransmission via a postsynaptic mechanism (Cai et al., 2013) . In summary, the present study has demonstrated that 5-HT 7 receptor activation in rat hippocampal neurones signals a PKA-dependent phosphorylation of Ser 845 within the GluA1 AMPA receptor subunit that results in increased levels of pGluA1(Ser 845 ) subunits within the neuronal membrane.
These changes are likely to underlie the observed enhanced AMPA receptor-mediated neurotransmission within the rat hippocampus in vitro and in vivo.
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http://dx.doi.org/10.1111/bph.13432 Figure S5 Histologically marked recording sites from electrophysiological experiments. A: Schematic depicting the hippocampus, the CA3 region, and the approximate positioning of recording electrodes for in vitro and in vivo experiments. B: A light microscope image of a cryosectioned hippocampus recovered from an in vivo electrophysiological experiment in which the recording site has been marked by iontophoretic administration of the dye Chicago Sky Blue (blue dot; arrow). C: Brightfield and fluorescent (D) images of a typical Lucifer yellow-filled CA3 pyramidal neurone from which patchclamp recordings were made.
